Remove Antibody Remove Bioassay Remove Development
article thumbnail

Toregem BioPharma and WuXi Biologics to partner for antibody development

Pharmaceutical Technology

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Under the MoU, the companies will form a collaboration for the development of TRG035, which targets USAG-1 to treat congenital adentia.

Antibody 130
article thumbnail

Cell and Gene Therapy Bioassay – A Prerequisite for the ATMPs Development

Roots Analysis

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. In fact, from year 2016 to 2020 more than 300 IND filing for cell and gene therapy product have been recorded, indicating that several developers and innovators are more attracted towards the cell and gene therapies.